Editor's note

This article was originally published on 26 March 2014 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.

The JCVI reversal

In March 2014 the UK Joint Committee on Vaccines and Immunisation (JCVI) announced it now recommends the inclusion of Novartis Vaccines' meningococcal group B vaccine Bexsero® (4CMenB) in the UK national immunisation programme, to be given at 2, 4 and 12 months of age. This is a dramatic reversal of the same committee's June 2013 interim statement that the vaccine was unlikely to be cost-effective "at any vaccine price" - a decision that had caused enormous disappointment across the meningitis research and patient community.

What changed in the model

The revised JCVI cost-effectiveness analysis incorporated several new inputs: revision of quality-of-life losses to include the short-term acute phase of invasive meningococcal disease (IMD); inclusion of quality-of-life losses to family members; revised disease incidence figures considered more representative of average rates; new data on sequelae rates; and inclusion of a proportion of NHS litigation costs associated with meningococcal disease. The result tipped the cost-effectiveness calculation in favour of the programme.

UK Incidence
614

Cases of meningococcal group B disease in England and Wales in 2011/12, representing ~87% of all meningococcal cases

"Once again the UK leads the way in large-scale implementation of preventative meningococcal vaccination, as it did with MenC back in 1999."

Market implications

VacZine Analytics had previously forecast 5-year cumulative global revenues for a MenB vaccine in the range of €1.4-5.7 billion from launch. The JCVI's proposal for 3 rather than 4 doses, absence of catch-up vaccination for older children, and no current adolescent programme suggest revenues will track towards the lower end of this range - but the UK decision as an early adopter precedent should catalyse sequential country introductions. With the UK decision, Novartis could finally reap a financial return on 17 years of investment.

Pfizer watches closely

Pfizer, having received FDA Breakthrough Therapy Designation for its bivalent rLP2086 MenB candidate, intended to submit its Biologics License Application to the US FDA by mid-2014. The UK adolescent and infant experience with Bexsero® would be closely observed as it builds the global MenB evidence base relevant to Pfizer's US adolescent target population.